Skip to main content
NUTRITION 2026 Main banner

Dietary Bioactive Components

Category: Dietary Bioactive Components (II) (Poster Session)

Dietary Bioactive Components (II) (Poster Session)

(P31-19-26) Effects of Flavonoid Supplementation on Hepatic Steatosis and Liver Enzymes in Adults with MASLD: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Monday, July 27, 2026
9:30 AM - 10:30 AM ET
Location: Poster Board D-64
Disclosure(s):
Natasha Leenabanchong, Medical Student: No relevant financial relationship(s) with ineligible companies to disclose.
Krit Pongpirul, MD, MPH, PhD.: No relevant financial relationship(s) with ineligible companies to disclose.


Objectives: To evaluate the effects of flavonoid supplementation on hepatic steatosis and liver enzymes in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or non-alcoholic fatty liver disease (NAFLD).

Methods: A systematic review and meta-analysis of randomized controlled trials was conducted using searches of PubMed and Embase without date or language restrictions. Eligible studies included adults with MASLD or NAFLD receiving purified oral flavonoid supplementation compared with placebo, no treatment, standard care, or lifestyle modification alone. The primary outcomes were changes in hepatic steatosis and alanine aminotransferase (ALT), while secondary outcomes included aspartate aminotransferase (AST), insulin resistance (HOMA-IR), and metabolic parameters. Risk of bias was assessed using the Cochrane RoB-2 tool. A random-effects meta-analysis was performed to pool mean differences (MD) with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic.

Results: Nine randomized controlled trials comprising 351 participants were included. Flavonoid supplementation significantly reduced ALT compared with control (MD −3.97 U/L; 95% CI −6.29 to −1.65; p = 0.0008; I² = 0%). Insulin resistance was also significantly improved, with reduced HOMA-IR (MD −0.68; 95% CI −1.05 to −0.32; p = 0.0003; I² = 0%). However, no statistically significant effects were observed for AST (MD −1.89 U/L; 95% CI −4.24 to 0.46; p = 0.12) or body mass index (BMI) (MD −0.47 kg/m²; 95% CI −1.50 to 0.56; p = 0.37).

Conclusions: Flavonoid supplementation may improve liver function and insulin resistance in patients with MASLD, as indicated by significant reductions in ALT and HOMA-IR. However, effects on AST and BMI were not statistically significant. Larger randomized trials are needed to confirm the role of flavonoids as a therapeutic strategy for MASLD.

Funding Sources: Thailand Science Research and Innovation (TSRI); National Science, Research and Innovation Fund (Thailand); Chulalongkorn University (Second Century Fund and Graduate Scholarship Programme).